# 4,5-Diethyl-3′-Ethoxy-Pyroflavone (isolated from Vitex negundo L.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/45-diethyl-3-ethoxy-pyroflavone-isolated-from-vitex-negundo-l
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 4,5-diethyl-3′-ethoxyflavone, Pyroflavone ethoxy derivative, Vitex negundo isolated flavone, Diethylethoxypyroflavone

## Overview

4,5-Diethyl-3′-ethoxy-pyroflavone is a structurally modified flavone compound bearing ethyl substituents at positions 4 and 5 and an ethoxy group at the 3′ position of the B-ring, modifications that are hypothesized to enhance membrane permeability and target-binding affinity relative to the parent flavone scaffold. Preclinical bioassay data indicate this compound exhibits statistically significant antifilarial activity in a dose-dependent manner against filarial parasites, representing one of the few structurally defined flavone analogs with documented antiparasitic potency derived from Vitex negundo phytochemistry.

## Health Benefits

- **Antifilarial Activity**: The compound demonstrates dose-dependent lethal or motility-inhibiting effects on filarial larvae and adult worms in preclinical models, suggesting potential utility as a lead molecule in lymphatic filariasis drug discovery programs.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential**: As a flavone derivative related to compounds found in Vitex negundo, it is structurally positioned to inhibit cyclooxygenase (COX-2) and lipoxygenase pathways, though direct enzymatic assay data for this specific analog remain unpublished in open literature.
- **Antiparasitic Scaffold Utility**: The pyroflavone core serves as a pharmacophore for structure-activity relationship (SAR) studies targeting helminths and protozoa, with ethyl and ethoxy substitutions altering lipophilicity and thus parasite membrane penetration.
- **Antioxidant Framework**: Flavone analogs bearing alkoxy substitutions on the B-ring generally retain the capacity to scavenge [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) via electron donation from the aromatic hydroxyl and ether systems, a property relevant to reducing oxidative stress in parasite-infected tissue.
- **Potential Macrofilaricidal Lead Activity**: Preliminary biological screening suggests activity against adult-stage filarial worms, which is pharmacologically distinct from and more therapeutically valuable than microfilaricidal action alone, positioning this compound as a candidate for further optimization.
- **Cytotoxic Selectivity Research**: Structural analogs in the pyroflavone class have been studied for selective cytotoxicity toward parasite cells over host mammalian cells, a critical safety criterion for antiparasitic drug development that motivates continued investigation of this specific derivative.

## Mechanism of Action

The precise molecular mechanism of 4,5-diethyl-3′-ethoxy-pyroflavone has not been fully elucidated in published literature; however, based on its flavone scaffold and the pharmacology of closely related Vitex negundo-derived flavones, several plausible mechanisms are proposed. The compound likely interferes with helminth neuromuscular function by modulating ion channel conductance or [acetylcholine](/ingredients/condition/cognitive)sterase activity, which are established targets of antifilarial agents, leading to parasite paralysis and death at sufficient concentrations. The ethoxy substituent at the 3′ position increases lipophilicity relative to unsubstituted flavones, facilitating partitioning into the lipid-rich cuticle and tegument of filarial nematodes, thereby enhancing intracellular access to enzymatic targets such as [glutathione](/ingredients/condition/detox)-S-transferase and superoxide dismutase that parasites rely on for oxidative defense. Additionally, the compound may suppress host-side inflammatory cytokine cascades (TNF-α, IL-6) through NF-κB pathway modulation, a secondary mechanism consistent with the broader [anti-inflammatory](/ingredients/condition/inflammation) pharmacology documented for Vitex flavone derivatives.

## Clinical Summary

There are no published human clinical trials evaluating 4,5-diethyl-3′-ethoxy-pyroflavone as a standalone therapeutic agent. Its clinical relevance is currently confined to its status as a bioactive lead compound identified through preclinical antifilarial screening of Vitex negundo-derived flavone analogs. Outcomes such as microfilaria clearance rates, adult worm burden reduction, and safety tolerability in humans have not been measured for this specific compound, and no effect sizes or confidence intervals from controlled human studies are available. The clinical pathway for this compound, should research progress, would likely involve pharmacokinetic profiling, toxicological assessment in animal models, and eventual Phase I dose-escalation studies before any clinical efficacy conclusions could be drawn.

## Nutritional Profile

4,5-Diethyl-3′-ethoxy-pyroflavone is a pure secondary metabolite and flavone analog with no independent macronutrient or micronutrient nutritional value; it does not contribute calories, protein, lipids, carbohydrates, vitamins, or dietary minerals in any meaningful quantity. Its molecular formula is characteristic of a substituted flavone backbone (C15 chromone core) with ethyl groups at positions 4 and 5 and an ethoxy substituent on the B-ring, contributing to a calculated molecular weight estimated in the range of approximately 310–340 g/mol depending on the exact substitution pattern. Bioavailability of flavone analogs of this structural class is generally limited by poor aqueous solubility, moderate to high plasma protein binding, and susceptibility to Phase I (cytochrome P450-mediated O-deethylation) and Phase II (glucuronidation, sulfation) hepatic [metabolism](/ingredients/condition/weight-management), though specific pharmacokinetic parameters for this compound have not been published. No dietary reference intakes, recommended daily allowances, or tolerable upper intake levels exist for this compound.

## Dosage & Preparation

- **Isolated Compound (Research Grade)**: Used exclusively in preclinical laboratory settings; no standardized human dosage has been established or validated.
- **Source Plant Preparation (Traditional)**: Roots of Vitex negundo are traditionally boiled in water to prepare decoctions used in Ayurvedic medicine for [inflammatory](/ingredients/condition/inflammation) and parasitic conditions; this preparation does not yield isolated pyroflavone in defined concentrations.
- **Solvent Extraction (Research)**: Laboratory isolation typically employs sequential solvent extraction (hexane, ethyl acetate, methanol) followed by column chromatography on silica gel to obtain the purified compound from Vitex negundo root or leaf material.
- **Effective Antifilarial Dose (Preclinical)**: Dose-dependent antifilarial activity has been reported in bioassay settings, but specific minimum effective concentrations (MEC) or lethal concentrations (LC50) for this compound are not uniformly reported in accessible literature.
- **No Commercial Supplement Form Available**: This compound is not currently available as a dietary supplement, nutraceutical product, or over-the-counter preparation; it exists solely as a research chemical or phytochemical isolate.

## Safety & Drug Interactions

No formal toxicological studies, safety pharmacology assessments, or human adverse event data are available in published literature for 4,5-diethyl-3′-ethoxy-pyroflavone, making a definitive safety profile impossible to establish at this time. Given its structural classification as an alkylated and alkoxylated flavone analog, theoretical concerns include hepatotoxic potential from alkyl chain metabolites, inhibition of cytochrome P450 enzymes (particularly CYP1A2, CYP3A4) that could precipitate pharmacokinetic drug-drug interactions with anticoagulants, immunosuppressants, or antiretroviral medications, and possible hormonal activity given the structural similarity of some flavones to phytoestrogens. Contraindications have not been formally defined; however, standard precautionary guidance for uncharacterized phytochemical isolates advises against use in pregnancy, lactation, pediatric populations, or individuals with hepatic impairment until safety data are available. The absence of safety data is a critical gap that must be addressed before any consideration of human administration outside of strictly regulated clinical research settings.

## Scientific Research

Published scientific evidence for 4,5-diethyl-3′-ethoxy-pyroflavone is limited to a small number of phytochemical and bioactivity screening studies, most of which are in vitro or in vivo animal models rather than controlled clinical trials in humans. The compound has been identified and characterized in the context of systematic phytochemical investigations of Vitex negundo, with antifilarial bioassays confirming dose-dependent activity, but specific sample sizes, effect sizes, IC50 values, and experimental animal models used in these studies are not comprehensively reported in publicly accessible secondary literature. No peer-reviewed human clinical trials, randomized controlled trials (RCTs), or systematic reviews specifically addressing this compound have been identified, and its current evidence base is best classified as early-stage preclinical. Researchers interested in this compound must consult original phytochemistry and parasitology journals, particularly those focused on South Asian medicinal plant pharmacology, as the gray literature surrounding Vitex antifilarial research is substantial but methodologically heterogeneous.

## Historical & Cultural Context

The compound itself has no independent historical or cultural use, as it is a defined chemical entity isolated and characterized through modern phytochemical methods rather than a traditional preparation. Its parent plant, Vitex negundo (known as Nirgundi in Sanskrit and Five-leaved chaste tree in English), has been used for over two millennia in Ayurvedic medicine for treating pain, inflammation, paralytic conditions, and skin diseases, with classical Ayurvedic texts including the Charaka Samhita and Sushruta Samhita referencing preparations from its leaves, roots, and seeds. In traditional Chinese medicine, Vitex negundo is known as Huang Jing Zi and has been employed for similar [anti-inflammatory](/ingredients/condition/inflammation) applications, and in Southeast Asian ethnomedicine, root decoctions have been applied to treat fevers and worm infestations consistent with the antifilarial activity now being documented in its isolated flavone constituents. The modern scientific investigation of this specific pyroflavone analog reflects a broader trend of systematic bioactivity-guided fractionation of Vitex species to identify and structurally optimize the individual molecular contributors to the plant's documented medicinal properties.

## Synergistic Combinations

No formal synergy studies have been conducted for 4,5-diethyl-3′-ethoxy-pyroflavone in combination with other compounds; however, based on the broader pharmacology of antifilarial agents, combination with ivermectin or albendazole (standard-of-care antifilarials) could theoretically produce additive or synergistic parasite-killing effects if the flavone operates through a mechanistically distinct pathway such as [oxidative stress](/ingredients/condition/antioxidant) induction rather than tubulin disruption or chloride channel modulation. Within the Vitex negundo phytochemical context, the compound may act synergistically with co-isolated iridoids such as agnuside and aucubin, which contribute [anti-inflammatory](/ingredients/condition/inflammation) activity that could reduce the immunopathological burden of filarial infection alongside direct antiparasitic activity. Formulation with phospholipid complexes (phytosomes) or cyclodextrin encapsulation could enhance the bioavailability of this lipophilic flavone, indirectly amplifying its biological effect at lower administered doses.

## Frequently Asked Questions

### What is 4,5-diethyl-3′-ethoxy-pyroflavone and where does it come from?

4,5-Diethyl-3′-ethoxy-pyroflavone is a structurally modified flavone compound that has been isolated from Vitex negundo L., a medicinal shrub native to tropical Asia. It belongs to the pyroflavone subclass of flavonoids and is characterized by ethyl substituents at positions 4 and 5 of the chromone ring system and an ethoxy group at the 3′ position of the B-ring, modifications that distinguish it from simpler natural flavones found in the parent plant.

### What is the main biological activity of 4,5-diethyl-3′-ethoxy-pyroflavone?

The principal documented bioactivity of 4,5-diethyl-3′-ethoxy-pyroflavone is antifilarial activity, meaning it demonstrates the ability to kill or immobilize filarial parasites (nematodes responsible for diseases such as lymphatic filariasis) in a dose-dependent manner in preclinical bioassay systems. This positions the compound as a pharmacological lead molecule of interest for tropical neglected disease research, though no human clinical data currently support its use as a therapeutic agent.

### Has 4,5-diethyl-3′-ethoxy-pyroflavone been tested in human clinical trials?

No human clinical trials have been published for 4,5-diethyl-3′-ethoxy-pyroflavone as of available literature. All documented evidence for this compound comes from preclinical phytochemical isolation and in vitro or in vivo bioactivity screening studies, and it has not progressed to formal Phase I, II, or III clinical evaluation in human subjects.

### Is 4,5-diethyl-3′-ethoxy-pyroflavone available as a dietary supplement?

No, 4,5-diethyl-3′-ethoxy-pyroflavone is not available as a commercial dietary supplement or nutraceutical product. It exists only as an isolated research chemical used in laboratory pharmacological investigations, and no standardized supplement formulations, dosage recommendations, or regulatory approvals for human use have been established.

### What are the safety concerns associated with 4,5-diethyl-3′-ethoxy-pyroflavone?

Formal safety data for 4,5-diethyl-3′-ethoxy-pyroflavone are entirely absent from published literature, making it impossible to define a safe human dose, identify contraindications, or characterize drug interactions with confidence. Theoretical concerns based on its flavone structure include potential inhibition of liver cytochrome P450 enzymes and possible estrogenic activity, and precautionary principles strongly advise against human consumption outside of formally approved clinical research protocols.

### What research evidence supports the antifilarial potential of 4,5-diethyl-3′-ethoxy-pyroflavone?

Preclinical laboratory studies have demonstrated that this compound exhibits dose-dependent activity against filarial larvae and adult worms, showing both lethal effects and motility inhibition in controlled models. These findings have positioned it as a promising lead molecule for further development in lymphatic filariasis drug discovery programs. However, the research remains primarily in the preclinical stage, with no published human clinical efficacy trials to date.

### How does the chemical structure of 4,5-diethyl-3′-ethoxy-pyroflavone relate to its biological activity?

As a pyroflavone derivative with diethyl and ethoxy substitutions, this compound's structure is similar to other bioactive flavonoids found in Vitex negundo, which typically exhibit anti-inflammatory and antioxidant properties. The specific positioning of the ethoxy group at the 3′ position and diethyl groups at the 4,5 positions likely contribute to its enhanced potency against parasitic organisms compared to parent flavone structures. Structural modifications like these are commonly used in medicinal chemistry to optimize biological activity and selectivity.

### Why is 4,5-diethyl-3′-ethoxy-pyroflavone not widely available as a commercial supplement despite its biological potential?

This compound remains in the early-stage research phase with insufficient human safety and efficacy data to meet regulatory requirements for dietary supplement or pharmaceutical approval. The isolation process from Vitex negundo is likely complex and expensive, making commercial production economically challenging without established clinical demand. Most research-stage phytochemicals require substantial clinical validation before manufacturers invest in scale-up production and regulatory submissions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*